Novo Nordisk wins hard-fought FDA approval for once-daily hemophilia med Alhemo
23rd December 2024 Uncategorised 0The FDA approved Novo Nordisk’s tissue factor pathway inhibitor (TFPI) antagonist concizumab as a once-a-day treatment to prevent or curb the frequency of bleeding episodes in patients ages 12 and older who have hemophilia A or B with inhibitors. The green light follows a rejection in 2023 and a trial pause over safety concerns several years before that.
More: Novo Nordisk wins hard-fought FDA approval for once-daily hemophilia med Alhemo
Source: fierce